
![]()
Novartis Oncology in Croatia
About Novartis Oncology Croatia
Novartis, one of the biggest and most respected international pharmaceutical companies, opened a Representative office in Croatia in 1997. Novartis Oncology is a part of this office. We employ highly educated individuals who contribute to the company and customers with their specific knowledge and experience.
Our Focus
Novartis Oncology Croatia is focused on therapy of oncological diseases and has already been cooperating very successfully with oncologists, hematologists, urologists, gastroenterologists and other related specialties for 10 years. All this with one and only purpose - to help patients under treatments and improve the quality of their lives.
The patient and the quality of his/her life are the main focus of Novartis Oncology.
Novartis Oncology Croatia focuses on the following diseases: chronic myeloid leukemia, gastrointestinal stromal tumors, hormone responsive breast cancer, bone metastasis in solid tumors and multiple myeloma, GEP/NET tumors and acromegaly.
Novartis Oncology products registered in the Croatian market are: GLIVEC, ZOMETA, SANDOSTATIN, SANDOSTATIN LAR and EXJADE.
Novartis Oncology is a pharmaceutical company that invests significant resources in Research and Development. Our goal at Novartis Oncology Croatia is to make all of our drugs available in the Croatian market.
Useful links
Agency for Medicinal Products and Medical Devices
Croatian Institute for Health Insurance
Croatian National Institute for Public Health
Croatian Leukemia and Lymfoma Societyi
Contact Information
For additional information, please contact us at:
Novartis Pharma Services Inc.
Subsidiary in Croatia
Zaharova 7b, 10000 Zagreb, Croatia
Phone: +385 1 6274 235
Novartis Onkologija u Hrvatskoj
Novartis, jedna od najvecih i najuglednijih medunarodnih farmaceutskih tvrtki u svijetu, 1997. godine je otvorila predstavništvo u Hrvatskoj. Dio tog predstavništva je i Novartis Onkologija. Novartis Onkologija usmjerena je na podrucje lijecenja onkoloških bolesti i vec 10 godina uspješno suraduje s onkolozima, hematolozima, urolozima, gastroenterolozima, radioterapeutima i drugim srodnim specijalistima, a sve s jednim ciljem - pomoci u lijecenju bolesnika i poboljšati njihovu kvalitetu života. U Novartis Onkologiji u Hrvatskoj rade visokoobrazovani strucnjaci koji svojim znanjem i iskustvom pridonose uspjehu i razvoju tvrtke.
Podrucje interesa
Bolesnik i poboljšanje kvalitete njegova života krajnji su cilj Novartis Onkologije kako na globalnoj tako i na lokalnoj razini.
Bolesti koje su, trenutno, u središtu Novartis Onkologije u Hrvatskoj su: kronicna mijeloicna leukemija, gastrointestinalni stromalni tumori, hormonu ovisan karcinom dojke, koštane metastaze solidnih tumora i multiplog mijeloma, akromegalija i gastroenteropankreaticni neuroendokrini tumori.
Novartis Onkologija na tržištu Hrvatske ima registrirane slijedece proizvode: GLIVEC, ZOMETA, FEMARA, SANDOSTATIN, SANDOSTATIN LAR i EXJADE.
Novartis Onkologija je tvrtka koja ulaže znatna sredstva u istraživanje i razvoj, tako da u pripremi ima i nove molekule. Zadatak Novartis Onkologije Hrvatska je uciniti sve svoje lijekove dostupnima na tržištu Hrvatske.
Korisni linkovi
Ministarstvo zdravstva Republike Hrvatske
Agencija za lijekove i medicinske proizvode
Hrvatski Zavod za Zdravstveno osiguranje
Hrvatski zavod za javno zdravstvo
Hrvatska Udruga Leukemije i Liomfomi
Kontakt
Za sve dodatne informacije, lijepo Vas molimo, kontaktirajte nas direktno!
Novartis Pharma Services Inc.
Predstavništvo u Hrvatskoj
Zaharova 7b
10000 Zagreb, Hrvatska
Tel.: + 385 1 6274 235
PRODUCTS
At Novartis Oncology, we strive to provide a broad range of innovative, practical solutions and authoritative resource therapies.
CAREERS AT NOVARTIS

Our success depends entirely on the creativity, performance and achievement of our associates at all levels.
RESEARCH INNOVATION
Novartis maintains the most promising oncology drug pipeline in the industry to treat and help people around the world.
STAY CONNECTED TO THE CANCER RESOURCE CENTER
Receive "Oncology in the News" by email weekly.